The PlantEXT vision is to develop the most effective, clinically evidenced medical cannabis formulations that improve the quality of life for patients across the globe.
The PlantEXT innovative approach to development is based on the knowledge and years of experience our team holds in the pharmaceutical industry, from discovery and feasibility to cGMP. By utilizing a systematic approach to development, the PlantEXT know-how to medical cannabis development is in tandem with the pharmaceutical Quality by Design approach (QbD). Initiating predefined objectives and emphasizing product and process understanding and process control, our research and development is based on sound science and quality risk management. Our mission is to assure the highest quality, clinically evidenced, safe and effective medical cannabis solutions that solve unmet needs for the consumer.
Israel has become the world leader in the research and development of the medical uses of cannabis. The extensive work that has been done during the past half century has led to a rich array of research and knowledge taking place in Israel with many international academic institutions and companies utilizing the country for research and clinical trials. This has contributed to a major competitive advantage based on knowledge time and experience. Canada has been the pioneer for the cannabis capital market and the basis for it’s global advancement.
Globally renowned auditor, advisor and consultant to the world’s largest consumer and retail companies. He has deep expertise in audit, tax, risk, governance, M&A and transformation. Former Global and Canadian Chair, Consumer & Retail National Leader, High Growth Markets Canada KPMG LLP
Founder of PlantEXT Limited and its parent company, Israel Plant Sciences Limited
Former researcher and department head in the Agricultural Research Organization, Volcani Center, Israel
IBD Research
Agricultural Research Organization, Volcani Center
Israel
More than 25 years of experience in operations, business development, strategic marketing
Expertise in bringing new products to market.Has taught entrepreneurship at two of Israel’s top universities.
PhD in Chemistry – Johns Hopkins University
39 years at TEVA Pharmaceuticals;
Sr. Director R&D, Global Product Strategy and Initiation, Chemistry R&D
Chief Medical Officer and Director
Served as Senior Director of Pharmaceutics and Director of Formulation Development at TEVA
President and Chief Executive Officer of Shadchen Resources Intermediaries Inc., which has successfully facilitated the takeover of several Canadian mining resources by foreign investors. He has cofounded a technology startup company (Tilr), and has been a Director of several technology startups.
A leading researcher and scientist – she has led and managed R&D of several pharmaceutical innovations and clinical trials.
Ph.D. in Medical Science- Technion
President and CEO of Cancap Investments Limited, a private merchant bank. CEO, President and a Director of James Bay Resources Limited (CSE:JBR) and Crestar Integrated Natural Resources Limited (CINL). Co-Chairman and Founder of Cerrado Gold, a precious metals exploration and production company in Brazil and Argentina. Founder and Executive chairman of Tilr Corporation, a leading patent pending on demand recruitment technology platform.
Founder of PlantEXT Limited and its parent company, Israel Plant Sciences Limited
Former researcher and department head in the Agricultural Research Organization, Volcani Center, Israel
Director of Jewish National Fund
Chairman of 18th Maccabiah Organizing Committee
Chairman of Kfar Maccabiah
President and Chief Executive Officer of Shadchen Resources Intermediaries Inc., which has successfully facilitated the takeover of several Canadian mining resources by foreign investors. He has cofounded a technology startup company (Tilr), and has been a Director of several technology startups.
Globally renowned auditor, advisor and consultant to the world’s largest consumer and retail companies. He has deep expertise in audit, tax, risk, governance, M&A and transformation. Former Global and Canadian Chair, Consumer & Retail National Leader, High Growth Markets Canada KPMG LLP
Professor Emeritus of The Hebrew University of Jerusalem’s Institute for Drug Research, is globally acknowledged as the father of cannabinoid research. His pioneering work has proven to be of central importance in pharmacology, physiology, and medicine.
President and Chief Executive Officer of Shadchen Resources Intermediaries Inc., which has successfully facilitated the takeover of several Canadian mining resources by foreign investors. He has cofounded a technology startup company (Tilr), and has been a Director of several technology startups.
Managing Director at Farber, he co-leads the Performance Acceleration practice, a group that helps executives overcome strategic and operational challenges to uncover potential and unleash performance.
Internal medicine specialist
Graduate of Stanford Biodesign Innovation Fellowship
Founder and leader of ART Health Care Ltd., TopgeniX Inc., SynVaccine Ltd.
Inventor of several pharma and medical device patents
With roots in both Canada and Israel, the hotbeds of cannabis innovation and commercialization; PlantEXT is positioned at the forefront of science-based medical cannabis product development. PlantEXT is developing truly effective solutions based on proprietary research and validation techniques.
PlantEXT has entered into a license agreement with The Government of the State of Israel and has funded research at the ARO (Agricultural Research Organization) conducted by Dr. Hinanit Koltai. Thus, acquiring the exclusive global rights to commercialize ARO's intellectual property ("IP") and methodology to quantify the anti-inflammatory activity of cannabis extracts on human biopsies and a patent for a composition for the treatment of Inflammatory Bowel Disease (IBD). PlantEXT and the State of Israel's ARO, have successfully refined earlier discoveries to develop active, anti-inflammatory formulations of cannabinoids and terpenes derived from cannabis. In vitro testing on human cell lines and ex vivo testing on inflamed colon biopsies of patients with inflammatory bowel disease ("IBD") has enabled the PlantEXT team to identify, at the molecular level, synergistic combinations of cannabinoids and terpenes to help reduce inflammation for a variety of inflammation induced diseases.
2300 Yonge Street, Suite 1709
Toronto, ON
M4P 1E4
Developing and commercializing the most effective, clinically evidenced medical cannabis formulations that improve the quality of life for patients across the globe.
